外周血作为一种非侵入性的组织活检替代方案，正在成为治疗恶性胶质瘤（GBM）生物标志物开发的重要手段。然而，由于缺乏强大的检测方法，在临床中广泛应用的血液生物标志物还未被确定。在此，我们描述了RNA测序中全血球蛋白还原（WBGR）的应用，并进行转录组分析以鉴定与GBM相关的转录组变化。通过使用WBGR，我们提高了信息读取的检测灵敏度，并在GBM血液中鉴定到差异基因表达。通过分析肿瘤组织，我们确定了GBM血液的转录组特征。进一步的功能富集分析把在GBM上变化最大的基因保留下来。随后的验证确定了一个由10个基因构成的面板，包括mRNA、长链非编码RNA和微小RNA（即GBM-Dx面板），具有在早期诊断或临床管理GBM方面的翻译潜力。在此，我们报道了一种综合分析能力强的整合方法WBGR，用于血液标记物的鉴定。©2023作者。

Peripheral blood is gaining prominence as a noninvasive alternative to tissue biopsy to develop biomarkers for glioblastoma (GBM); however, widely utilized blood-based biomarkers in clinical settings have not yet been identified due to the lack of a robust detection approach. Here, we describe the application of globin reduction in RNA sequencing of whole blood (i.e., WBGR) and perform transcriptomic analysis to identify GBM-associated transcriptomic changes. By using WBGR, we improved the detection sensitivity of informatic reads and identified differential gene expression in GBM blood. By analyzing tumor tissues, we identified transcriptomic traits of GBM blood. Further functional enrichment analyses retained the most changed genes in GBM. Subsequent validation elicited a 10-gene panel covering mRNA, long noncoding RNA, and microRNA (i.e., GBM-Dx panel) that has translational potential to aid in the early detection or clinical management of GBM. Here, we report an integrated approach, WBGR, with comprehensive analytic capacity for blood-based marker identification.© 2023. The Author(s).